|
|
Weekly View
October 8, 2021
|
|
Yesterday morning, the US Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, and ICER met to discuss our respective approaches for evaluating real-world evidence (RWE). Coordinated by the RWE Analytics Program within the FDA’s Center for Drug Evaluation and Research, the meeting aimed to promote an enhanced understanding of the general methodological issues related to RWE.
For our part, ICER presented our white paper outlining a framework for the optimal development and use of RWE for coverage and formulary decisions, we discussed our commitment to expand use of RWE in our value assessments, and we summarized the benefits and limitations of our recent RWE update to an earlier assessment of therapies for hereditary angioedema.
It was a promising discussion, and we look forward to working together to improve all forms of evidence so that patients everywhere can benefit from meaningful pharmaceutical innovation, fair pricing, and fair access.
OK, let’s see what else happened this week…
|
|
Yesterday we published our Evidence Report assessing mavacamten (MyoKardia and Bristol-Myers Squibb) for the treatment of hypertrophic cardiomyopathy (HCM). ICER’s Chief Medical Officer David Rind explained our findings:
“Hypertrophic cardiomyopathy is a genetic disorder of the heart muscle that can cause shortness of breath and chest pain, and also arrhythmias that can result in strokes or even sudden death. The evidence suggests that mavacamten may deliver important health benefits for patients with a low rate of side effects seen with other medications for HCM, but clinical experts differ in their opinions about the long-term clinical implications of mavacamten reducing left ventricular ejection fraction in some patients. This balance between potential benefits and harms will be a key component of the deliberations during our public meeting.”
At our October 22 virtual meeting, ICER's independent appraisal committee will review the evidence, hear further testimony from patients and other stakeholders, and deliberate over the treatment's comparative clinical effectiveness, other potential benefits, and long-term value for money.
|
|
|
San Francisco Business Times
|
Cell and gene therapies offer tremendous promise… along with tremendous prices. And as policymakers contemplate how best to determine what a “fair price” is for improving patients’ function, feeling and survival, they are increasingly turning to ICER’s value assessments.
The San Francisco Business Times notes that, as long as new treatments are truly transforming patients’ lives, ICER’s reviews justify a significant financial return for the drugmakers’ investors. Of all the cell and gene therapies ICER has reviewed, we’ve determined that more than half are cost-effective at their US launch prices -- a rate that far surpasses what we see across conventional maintenance medications that need to be administered year after year. While acknowledging the tension around pricey cell and gene therapies, the Business Times finds reason to be optimistic:
“Continuing the frank conversations prompted by patients and groups like ICER may be key to finding common ground among stakeholders.”
|
|
|
The pharmaceutical industry is lobbying to preserve its ability to unilaterally set Medicare drug prices, arguing that government negotiation would stifle industry’s willingness to develop new therapies in the future. PhRMA points to the recent CBO forecast suggesting that Medicare drug-price negotiation may lead to 0.5% fewer drugs in the first decade, and 5% fewer drugs over the second. (The CBO did not predict whether these undeveloped treatments would be novel or merely me-too.)
However, if policymakers structured Medicare negotiation to align each drug’s price to how well it improves patients’ lives, there may actually be an increase in meaningful innovation from the pharmaceutical industry. Instead of focusing on treatments that are only slightly better than the current standard of care, drugmakers would pursue a higher ROI by funneling their R&D capital toward the projects that could potentially demonstrate the greatest health gains over existing alternatives. As ICER’s President Steve Pearson explained to the Associated Press:
“The big argument is that if the government lays a finger on the process, somehow that is going to stifle innovation. [But] we can get even better innovation by being smart in how we pay.”
|
|
|
NICE, the health technology appraisal institute for England and Wales, is embarking on work to better understand how real-world evidence (RWE) studies can help fill evidence gaps and reduce uncertainties when the institute is developing guidance on drugs and other health care products. To support these efforts, this week NICE announced a new collaboration with Aetion to determine when and how RWE can support the agency’s decision-making.
Early last year, ICER and Aetion announced a similar collaboration to expand the use of RWE in US-based health technology assessments.
|
|
|
“The Institute for Clinical and Economic Review (ICER) performed an analysis of CGRP inhibitors and found that, overall, migraine patients had greater reductions in headache days per month compared to the use of other preventive medications. For certain patients for whom triptans are not effective, not tolerated, or are contraindicated, Nurtec ODT and Ubrelvy as acute migraine treatment agents are considered by ICER to be comparatively cost-effective."
|
|
|
MUST READS
Pink Sheet
Inside Health Policy
|
Despite Aduhelm’s troubling efficacy data and price, by law Medicaid must cover the treatment because the manufacturer has agreed to provide the mandatory rebate. However, individual states can develop their own medical necessity criteria as part of their coverage policies. Depending on the national coverage decision that CMS makes for Aduhelm in Medicare, Medicaid (the payer of last resort) could find itself significantly impacted.
Additionally, CMS’ innovation center can’t design payment models to test drug price controls until after Congress decides what it’s going to do on drug pricing, Center for Medicare and Medicaid Innovation Director Elizabeth Fowler said Tuesday, and the center also can’t design demos for Aduhelm until CMS determines what Medicare's national coverage policy will be.
|
|
|
With Congress considering legislation to allow Medicare to use its bargaining power to negotiate lower drug prices, large pharmaceutical companies are once again waging a campaign that contends that doing so would seriously harm the development of breakthrough drugs.
However, policy experts at the Commonwealth Fund and Arnold Ventures argue that industry’s affordability-or-innovation argument is a false choice. Smaller companies now account for the lion’s share of such breakthroughs. The key to supporting drug innovation is to increase NIH funding of the efforts that gives rise to these new companies, cut the costs and accelerate the speed of clinical trials, and reform patent law.
|
|
|
Axios
Inside Health Policy
|
Higher prices are the main reason why Medicare spending on drugs has exploded over the past decade, and the government should finally do something about it, members of the Medicare Payment Advisory Commission (MedPAC) said during a meeting yesterday.
For first-in-class therapies, they discussed basing payment on value, especially for drugs the get accelerated approvals based on surrogate endpoints, though that approach also could be used for other drugs, such as drugs in the six protected classes of Part D. A policy that combines approaches of setting payment based on cost effectiveness analysis and applying coverage with evidence development has the potential to control costs and encourage drug companies to study drugs following approvals.
|
|
|
Kaiser Health News
Inside Health Policy
|
As President Joe Biden’s government overhaul stalls in Congress, tensions are mounting over what changes -- if any -- could come for Americans at the pharmacy counter. Despite 2020 campaign promises to cut prices, Democrats have not coalesced around a plan as they seek to push through Congress a massive spending bill that would fund domestic policy initiatives, including new and enhanced health care programs. Party progressives focused on Medicare drug spending have supported a plan passed by the House last year that allows Medicare to negotiate prices. The CBO estimates it would save the government around $500 billion over 10 years, while reducing drug approvals by 0.5% during that initial decade.
|
|
|
The Wall Street Journal
Axios
STAT
|
Merck and its partner Ridgeback Biotherapeutics said their experimental COVID-19 pill helped prevent high-risk people early in the course of the disease in a pivotal study from becoming seriously ill and dying, a big step toward providing the pandemic’s first easy-to-use, at-home treatment.
The US has already agreed to pay Merck $1.2 billion for 1.7 million courses of treatment ($712 per regimen, or $17.80 per pill), should regulators green light use of molnupiravir. However, because molnupiravir was originally developed at Emory University from 2013-2020 with $35 million of taxpayer grants, some policy experts conclude that the federal government should already own rights to some of the treatment’s patents. And those experts argue that stronger government regulations should be in place to ensure that companies do not profit excessively from this sort of public funding.
|
|
|
The flexibility of emergency use authorizations, and allowing the FDA to accept more uncertainty during the pandemic so far, has ultimately aided its response to COVID-19, center directors said Tuesday at a workshop at the National Academies of Sciences, Engineering and Medicine. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, pointed to the agility of the EUAs, and the ability to quickly revoke any EUAs, as well as the transparency around those decisions as to what led to the evolution of the types of therapeutics that have been authorized.
|
|
|
Want to work for a fast-paced, mission-driven organization? Look no further! ICER is looking to expand our team, which includes a diverse set of clinicians, researchers, and policy experts.
|
Research and Health Economics
|
|
|
-
10/20: Myasthenia Gravis Final Evidence Report
-
11/16: Unsupported Price Increase Final Report
|
|
|
|
|
|
|
|